Lifeforce Capital
VC Fund
San Francisco, United States
Lifeforce Capital is a VC fund in San Francisco focused on Health Care and Biotechnology. Lifeforce Capital invests in digital health companies enabling new care delivery models or more efficient therapeutic development. Lifeforce Capital is headquartered in San Francisco, California.
- Total investments:
- 61
- Last investment:
- Lead investor:
- 15%
- Fund size:
- $50M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Lifeforce Capital invests in
Stages Lifeforce Capital invests in
Countries Lifeforce Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
John Noonan
|
|||
4 more contacts available
Investment Focus
Industry
- Health Care 30 (49%)
- Biotechnology 21 (34%)
- Medical 15 (25%)
- Therapeutics 9 (15%)
- Hospital 6 (10%)
Stage
- Series A 22 (36%)
- Series B 11 (18%)
- Seed 10 (16%)
- Series C 5 (8%)
- Venture - Series Unknown 2 (3%)
Country
- United States 37 (61%)
- United Kingdom 2 (3%)
- Brazil 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
John Noonan
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Carecubes
|
Carecubes develops medical-grade isolation technology that helps caregivers respond to pandemics in a calm and caring manner. | $6.5M / Series A / Mar 19, 2026 | |
Aspen Neuroscience
|
Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmetmedical needs, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs. | $115M / Series C / Nov 20, 2025 | |
Vilya
|
Vilya is a biotechnology company developing a novel class of drugs that precisely target the biology of disease. The company aims to create new medicines to leverage computing to make high throughput screening obsolete and cure diseases. | $21M / Series A / Jun 04, 2024 | |
Ochre Bio
|
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body.Ochre Bio is within the heartof Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market. | $30M / Series A / Oct 10, 2022 | |
Transition Bio
|
Transition Bio provides condensate technology for drug discovery and diagnostics. The company focuses on the discovery, analysis, and modulation of biological condensates, propelled by a differentiated technological capability that generates expansive drug development opportunities in a hypothesis-free manner. | $50M / Series A / Jun 02, 2022 | |
MindRight Health
|
MindRight Health's mission is to advance health equity by making mental health care radically accessible and inclusive of communities of color and low-income families. MindRight partners with healthcare payers and providers to offer culturally-responsive mental health coaching over a text message. MindRight's members receive a personalteam of coaches who proactively support them 7 days/week, 365 days/year. Through its service, MindRight is creating a continuum of support that does not generally exist for youth. For communities who do not traditionally engage in clinical services due to high stigma and lack of access, MindRight serves as an ongoing source of culturally responsive, nonclinical support. MindRight provides its partners with real-time data on community mental health needs to predict and prevent mental health crises in the communities. | $1.8M / Seed / May 24, 2022 | |
|
MindRight Health
|
MindRight Health's mission is to advance health equity by making mental health care radically accessible and inclusive of communities of color and low-income families. MindRight partners with healthcare payers and providers to offer culturally-responsive mental health coaching over a text message. MindRight's members receive a personalteam of coaches who proactively support them 7 days/week, 365 days/year. Through its service, MindRight is creating a continuum of support that does not generally exist for youth. For communities who do not traditionally engage in clinical services due to high stigma and lack of access, MindRight serves as an ongoing source of culturally responsive, nonclinical support. MindRight provides its partners with real-time data on community mental health needs to predict and prevent mental health crises in the communities. | $1.8M / Seed / May 24, 2022 | |
Character Biosciences
|
Biopharmaceutical research and development company that's an affiliate of Clover Health | $18M / Series A / May 17, 2022 | |
|
Aspen Neuroscience
|
Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmetmedical needs, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs. | $147.5M / Series B / May 09, 2022 | |
Vivante Health
|
Since 2016, Vivante Health has been revolutionizing digestive health and wellness, one person at a time. Our category-defining digital health solutions provide personalized, comprehensive care for people with digestive conditions. Our all-in-one digestive health program GIThrive® combines clinically-backed interactive tech, targeted nutrition, and24/7 personal support to improve digestive disease outcomes, and reduce the cost of care. GIThrive is used by large employers and health plans to reduce the costs of chronic disease, improve employee health, and workplace absenteeism. | $16M / Series A / Mar 08, 2022 | |
| See all 61 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Lifeforce Capital invest in?
Lifeforce Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 61 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Lifeforce Capital?
Public channels for Lifeforce Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Lifeforce Capital?
The team at Lifeforce Capital includes John Noonan (Founder and Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
